#neuropathology — Wednesday, April 01, 2026 (1 items)
| 0 | 💬 0 |
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
(nature.com)
|
Nature Medicine 2026-04-01 | #clinical trial #pharmacodynamics #neurodegeneration #antisense #neuropathology |